Patient-reported outcome (PRO)-based symptom assessment in patients with advanced lung cancer receiving first-line combination immunotherapy: a protocol for a multicenter, prospective, observational study

被引：0
|
作者：
Yuanle Deng
Han Hu
Rong Jia
Wei Dai
Dengfeng Wang
Purong Zhang
Peng Zhang
Kai Cheng
Jianning Tang
Yan Wen
Xiang Zhou
Qiuling Shi
Zhujuan Xiong
Jin Zhou
机构：
[1] Sichuan Cancer Hospital & Institute,Department of Clinical Nutrition, Sichuan Clinical Research Center for Cancer
[2] Sichuan Cancer Center,Department of Medical Oncology, Sichuan Clinical Research Center for Cancer
[3] Affiliated Cancer Hospital of University of Electronic Science and Technology of China,Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer
[4] Sichuan Cancer Hospital & Institute,Gynecologic Oncology Center, Sichuan Clinical Research Center for Cancer
[5] Sichuan Cancer Center,Department of Breast Surgery, Sichuan Clinical Research Center for Cancer
[6] Affiliated Cancer Hospital of University of Electronic Science and Technology of China,Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer
[7] Sichuan Cancer Hospital & Institute,Department of Pharmacy, Sichuan Clinical Research Center for Cancer
[8] Sichuan Cancer Center,Department of Gastrointestinal Surgery, Sichuan Clinical Research Center for Cancer
[9] Affiliated Cancer Hospital of University of Electronic Science and Technology of China,School of Public Health
[10] Sichuan Cancer Hospital & Institute,undefined
[11] Sichuan Cancer Center,undefined
[12] Affiliated Cancer Hospital of University of Electronic Science and Technology of China,undefined
[13] Sichuan Cancer Hospital & Institute,undefined
[14] Sichuan Cancer Center,undefined
[15] Affiliated Cancer Hospital of University of Electronic Science and Technology of China,undefined
[16] Sichuan Cancer Hospital & Institute,undefined
[17] Sichuan Cancer Center,undefined
[18] Affiliated Cancer Hospital of University of Electronic Science and Technology of China,undefined
[19] Sichuan Cancer Hospital & Institute,undefined
[20] Sichuan Cancer Center,undefined
[21] Affiliated Cancer Hospital of University of Electronic Science and Technology of China,undefined
[22] Sichuan Cancer Hospital & Institute,undefined
[23] Sichuan Cancer Center,undefined
[24] Affiliated Cancer Hospital of University of Electronic Science and Technology of China,undefined
[25] Chongqing Medical University,undefined
来源：
BMC Pulmonary Medicine | / 23卷
关键词：
Patient-reported outcome; Lung cancer; Immunotherapy; Immune-related adverse events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] PATIENT-REPORTED DISTRESS WITH IMMUNOTHERAPY-BASED FIRST-LINE TREATMENT FOR MNSCLC: A REAL-WORLD EVIDENCE STUDY
    Bodd, Monica
    Locke, Susan
    Antonia, Scott
    Crawford, Jeffrey
    Hartman, John
    Herring, Kris
    Ready, Neal
    Stinchcombe, Thomas
    Troy, Jesse
    Williams, Chakita
    Wolf, Steven
    Clarke, Jeffrey
    LeBlanc, Thomas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A665 - A665
  • [22] Remote symptom monitoring with patient-reported outcomes and nudges during lung cancer immunotherapy in China (PRO-NET): protocol for a randomised controlled trial
    Xia, Yiqi
    Guan, Xiaolong
    Shi, Zhenyu
    Luo, Yanan
    He, Ping
    BMJ OPEN, 2025, 15 (01):
  • [23] Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy
    Eton, David T.
    Yost, Kathleen J.
    Cella, David
    CLINICAL LUNG CANCER, 2006, 8 (02) : 99 - 109
  • [24] Patient-reported outcomes for patients with locally advanced or metastatic urothelial carcinoma under pembrolizumab: A prospective multicenter observational study.
    Annakib, Soufyan
    Bekoy, Yona Dibert
    Chevallier, Thierry
    Fiteni, Frederic
    Houede, Nadine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [25] Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study
    Harada, Daijiro
    Tamura, Tomoki
    Ninomiya, Kiichiro
    Kubo, Toshio
    Kuyama, Shoichi
    Tachibana, Sayaka
    Inoue, Koji
    Chikamori, Kenichi
    Kudo, Kenichiro
    Ochi, Nobuaki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    THORACIC CANCER, 2023, 14 (03) : 231 - 236
  • [26] Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy
    Buti, Sebastiano
    Bersanelli, Melissa
    Perrone, Fabiana
    Bracarda, Sergio
    Di Maio, Massimo
    Giusti, Raffaele
    Nigro, Olga
    Cortinovis, Diego L.
    Aerts, Joachim G. J. V.
    Guaitoli, Giorgia
    Barbieri, Fausto
    Ferrara, Miriam G.
    Bria, Emilio
    Grossi, Francesco
    Bareggi, Claudia
    Berardi, Rossana
    Torniai, Mariangela
    Cantini, Luca
    Sforza, Vincenzo
    Genova, Carlo
    Chiari, Rita
    Rocco, Danilo
    Della Gravara, Luigi
    Gori, Stefania
    De Tursi, Michele
    Di Marino, Pietro
    Mansueto, Giovanni
    Zoratto, Federica
    Filetti, Marco
    Citarella, Fabrizio
    Russano, Marco
    Mazzoni, Francesca
    Garassino, Marina C.
    De Toma, Alessandro
    Signorelli, Diego
    Gelibter, Alain
    Siringo, Marco
    Follador, Alessandro
    Bisonni, Renato
    Tuzi, Alessandro
    Minuti, Gabriele
    Landi, Lorenza
    Ricciardi, Serena
    Migliorino, Maria R.
    Tabbo, Fabrizio
    Olmetto, Emanuela
    Metro, Giulio
    Adamo, Vincenzo
    Russo, Alessandro
    Spinelli, Gian P.
    EUROPEAN JOURNAL OF CANCER, 2021, 150 : 224 - 231
  • [27] A prospective observational study of mobile application-based patient-reported outcomes (PRO) in advanced breast cancer: Interim baseline data from the MADELINE study
    Odom, D.
    Mitra, D.
    Hollis, K.
    Richardson, D.
    Kaye, J. A.
    McRoy, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
    Custodio, A.
    Carmona-Bayonas, A.
    Jimenez-Fonseca, P.
    Sanchez, M. L.
    Viudez, A.
    Hernandez, R.
    Cano, J. M.
    Echavarria, I.
    Pericay, C.
    Mangas, M.
    Visa, L.
    Buxo, E.
    Garcia, T.
    Rodriguez Palomo, A.
    Alvarez Mancenido, F.
    Lacalle, A.
    Macias, I.
    Azkarate, A.
    Ramchandani, A.
    Fernandez Montes, A.
    Lopez, C.
    Longo, F.
    Sanchez Bayona, R.
    Limon, M. L.
    Diaz-Serrano, A.
    Hurtado, A.
    Madero, R.
    Gomez, C.
    Gallego, J.
    BRITISH JOURNAL OF CANCER, 2017, 116 (12) : 1526 - 1535
  • [29] Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
    A Custodio
    A Carmona-Bayonas
    P Jiménez-Fonseca
    M L Sánchez
    A Viudez
    R Hernández
    J M Cano
    I Echavarria
    C Pericay
    M Mangas
    L Visa
    E Buxo
    T García
    A Rodríguez Palomo
    F Álvarez Manceñido
    A Lacalle
    I Macias
    A Azkarate
    A Ramchandani
    A Fernández Montes
    C López
    F Longo
    R Sánchez Bayona
    M L Limón
    A Díaz-Serrano
    A Hurtado
    R Madero
    C Gómez
    J Gallego
    British Journal of Cancer, 2017, 116 : 1526 - 1535
  • [30] Patient-reported outcome (PRO) assessment and reporting in first-line (1L) locally advanced or metastatic urothelial cancer (la/mUC) clinical trials: Results of a systematic literature review (SLR).
    Kearney, Mairead
    Macmillan, Tom
    Poritz, Julia
    Schreiber-Gosche, Sherrie
    Musat, Mihaela Georgiana
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345